SAB Biotherapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

SABS$3.07-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes In Stockholders’ Equity

Common stock · Series B Preferred Stock · Series A Preferred Stock · Treasury Stock
Shares · Amount · Shares · Amount · Shares · Amount · AdditionalPaid-In Capital · Shares · Amount · AccumulatedDeficit · Accumulated Other Comprehensive Income (Loss) · Total Stockholders’Equity
Balance at December 31, 2025	47,664,564	$4,766	638,558	$64		28,380		$3		$267,719,445		(54,665)		$(5,521,246)		$(110,895,167)		$186,510	$151,494,375
Stock-based compensation	—	—	—	—		—		—		5,459,911		—		—		—		—	5,459,911
Issuance of common stock for exercise of stock options	39,083	4			—		—		113,112		—	—	—		—		113,116
Issuance of common stock pursuant to vesting of restricted stock units	3,017	1	—	—		—		—		(1)		—		—		—		—	—
Payment of taxes withheld on issuance of restricted stock units	—	—	—	—		—		—		(4,571)		—		—		—		—	(4,571)
Conversion of Series B Preferred Stock into common shares	6,767,900	677	(67,679)	(7)		—		—		(670)		—		—		—		—	—
Conversion of Enrollment Warrants into Series B Preferred Stock	—	—	17,000	2		—		—		2,974,998		—		—		—		—	2,975,000
Issuance of common stock and prefunded warrants under the March 2026 Public Offering, net of issuance costs	19,324,677	1,932	—	—		—		—		79,248,697		—		—		—		—	79,250,629
Issuance of common stock under the March 2026 Public Offering Underwriters Option, net of issuance costs	2,000,000	200	—	—		—		—		7,237,800		—		—		—		—	7,238,000
Net loss	—	—	—	—		—		—		—		—		—		(18,868,885)		—	(18,868,885)
Foreign currency translation	—	—	—	—		—		—		—		—		—		—		137,517	137,517
Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment	—	—	—	—		—		—		—		—		—		—		(546,791)	(546,791)
Balance at March 31, 2026	75,799,241	$7,580	587,879	$59		28,380		$3		$362,748,721		(54,665)		$(5,521,246)		$(129,764,052)		$(222,764)	$227,248,301

Condensed Consolidated Statements of Changes In Stockholders’ Equity

Common stock · Series B Preferred Stock · Series A Preferred Stock · Treasury Stock
	Shares	Amount	Shares	Amount	Shares	Amount	AdditionalPaid-In Capital	Shares	Amount	AccumulatedDeficit	Accumulated Other Comprehensive Income (Loss)	Total Stockholders’Equity
Balance at December 31, 2024	9,343,533	$935	—	$—	42,019	$5	$155,794,142	(54,665)	$(5,521,246)	$(124,168,850)	$(135,410)	$25,969,576
Stock-based compensation	—	—	—	—	—	—	612,951	—	—	—	—	612,951
Issuance of common stock pursuant to vesting of restricted stock units	2,829	1	—	—	—	—	(1)	—	—	—	—	—
Payment of taxes withheld on issuance of restricted stock units	—	—	—	—	—	—	(2,072)	—	—	—	—	(2,072)
Net loss	—	—	—	—	—	—	—	—	—	(5,196,773)	—	(5,196,773)
Foreign currency translation	—	—	—	—	—	—	—	—	—	—	24,792	24,792
Unrealized loss, change in fair value of available-for-sale securities	—	—	—	—	—	—	—	—	—	—	(975)	(975)
Balance at March 31, 2025	9,346,362	$936	—	$—	42,019	$5	$156,405,020	(54,665)	$(5,521,246)	$(129,365,623)	$(111,593)	$21,407,499

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.